Galapagos NV

GXE

Company Profile

  • Business description

    Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

  • Contact

    Generaal De Wittelaan L11 A3
    Mechelen2800
    BEL

    T: +32 15342900

    E: [email protected]

    https://www.glpg.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    704

Stocks News & Analysis

stocks

Insignia Financial: Revised deal still attractive

The offer price is well above our fair value.
stocks

Undervalued ASX income play

Major development projects remain on schedule.
stocks

Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?

With the monetization of GenAI, here’s what we think of Alphabet’s stock

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,007.0065.500.73%
CAC 407,744.4153.81-0.69%
DAX 4024,041.90265.90-1.09%
Dow JONES (US)44,502.44179.370.40%
FTSE 1009,023.8110.820.12%
HKSE25,460.54330.511.32%
NASDAQ20,892.6981.49-0.39%
Nikkei 22541,307.011,532.093.85%
NZX 50 Index12,794.0639.68-0.31%
S&P 5006,309.624.020.06%
S&P/ASX 2008,743.6066.400.77%
SSE Composite Index3,596.6814.820.41%

Market Movers